a0292i
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK
plc
(the 'Company')
Transfer of Treasury Shares
On 21 March 2024, the Company transferred 27,800,000 ordinary shares of 31 1/4 pence
each ("Ordinary
Shares") that
were held by the Company in treasury ("Treasury
Shares") to
JPMorgan Chase Bank, N.A., the depositary of the Company's American
depositary receipts ("ADR")
programme, to procure the issuance and transfer of 13,900,000 ADRs
of the Company to the GlaxoSmithKline (US) Trust (the
"Trust"),
to be used to satisfy awards granted under the Company's Deferred
Annual Bonus Plan, Performance Share Plan and Share Value
Plan. The consideration received from
the trustee of the Trust of $41.93 per ADR, representing $20.965
per Ordinary Share, was funded by a contribution to the Trust from
GlaxoSmithKline LLC.
Following the transfer and as at 22 March 2024, the Company's
issued share capital consisted of 4,314,051,101 Ordinary Shares, of
which 169,171,155 were held as Treasury
Shares.
Therefore, the total number of voting rights in
the Company is 4,144,879,946. This figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.
Notifications may be sent to company.secretary@gsk.com.
V A Whyte
Company Secretary
22 March 2024
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: March
22, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|